Cargando…
Coadministration of kla peptide with HPRP-A1 to enhance anticancer activity
The apoptosis-inducing peptide kla (KLAKLAK)(2) possesses the ability to disrupt mitochondrial membranes and induce cancer cell apoptosis, but this peptide has a poor eukaryotic cell-penetrating potential. Thus, it requires the assistance of other peptides for effective translocation at micromolar c...
Autores principales: | Hao, Wenjing, Hu, Cuihua, Huang, Yibing, Chen, Yuxin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839859/ https://www.ncbi.nlm.nih.gov/pubmed/31703065 http://dx.doi.org/10.1371/journal.pone.0223738 |
Ejemplares similares
-
Co-administration of iRGD with peptide HPRP-A1 to improve anticancer activity and membrane penetrability
por: Hu, Cuihua, et al.
Publicado: (2018) -
In vitro Characterization of the Rapid Cytotoxicity of Anticancer Peptide HPRP-A2 through Membrane Destruction and Intracellular Mechanism against Gastric Cancer Cell Lines
por: Zhao, Jing, et al.
Publicado: (2015) -
Enhanced anticancer efficacy of paclitaxel through multistage tumor-targeting liposomes modified with RGD and KLA peptides
por: Sun, Jiawei, et al.
Publicado: (2017) -
Monomeric a-synuclein (aS) inhibits amyloidogenesis of human prion protein (hPrP) by forming a stable aS-hPrP hetero-dimer.
por: Yamashita, Satoshi, et al.
Publicado: (2021) -
Enhanced antitumor effects of the BRBP1 compound peptide BRBP1-TAT-KLA on human brain metastatic breast cancer
por: Fu, Bo, et al.
Publicado: (2015)